Home » Lianhua Qingwen Capsule caused controversy: Wang Sicong said that Yiling Pharmaceutical should be strictly investigated – Latest News – cnBeta.COM

Lianhua Qingwen Capsule caused controversy: Wang Sicong said that Yiling Pharmaceutical should be strictly investigated – Latest News – cnBeta.COM

by admin
Lianhua Qingwen Capsule caused controversy: Wang Sicong said that Yiling Pharmaceutical should be strictly investigated – Latest News – cnBeta.COM

Lianhua Qingwen Capsule is famous for being included in the National Health Commission’s list of recommended drugs for the diagnosis and treatment of new coronary pneumonia many times. Since the beginning of this year, the stock price of manufacturer Yiling Pharmaceutical has risen by more than 100%. Now, Yiling Pharmaceutical has been pushed to the forefront by Wang Sicong again.At noon on April 14, Wang Sicong forwarded a message on Weibo that Lianhua Qingwen Capsule was recommended by WHO, and said that “the China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical.”

access:

VIP members buy 1 and get 5: Free iQIYI half-year card, JD Plus, Baidu Netdisk, Dingdong grocery shopping

With Wang Sicong’s influence and topic-driven ability, it immediately aroused heated discussions.

But a few minutes later, Wang Sicong edited Weibo and deleted relevant remarks.

In this regard, the staff of Yiling Pharmaceutical Securities Department responded strongly:“Regarding the news on Weibo, please point out the specific problem and source, and we will answer the specific content.”

The staff member also stated:“From clinical trials, to specific experimental data, to being included in the new coronary pneumonia diagnosis and treatment plan, including indications and instructions, we have complete evidence and report disclosure. We can’t just ask questions just because of the three words ‘Wang Sicong’ . For some remarks on the Internet, just listen to it, investors please screen.”

It is worth mentioning that at noon on the 14th, just after Wang Sicong’s remarks fermented, Yiling Pharmaceutical’s stock price fell, and was later pushed to the daily limit by the strong capital. There are more than 40,000 orders.

See also  Fringe benefit, Borsa Italiana workers get 1,500 euros

According to the official website of Ling Pharmaceutical, Lianhua Qingwen Capsules/Granules are blindly compound traditional Chinese medicines. They are new patented drugs for the treatment of colds and flu developed under the guidance of the theory of TCM collateral diseases. The new drug variety has won the second prize of the National Science and Technology Progress Award and entered the US FDA clinical research for the treatment of influenza.

In terms of product features,Lianhua Qingwen has spectral antiviral effect on influenza A virus H1N1, H3N2, avian influenza H5N1, H9N2, SARS, EV71 virus, new coronavirus, etc. and community-acquired pneumonia.

Yiling Pharmaceutical said that since its listing, Lianhua Qingwen Capsules have been included in the diagnosis and treatment of respiratory virus infectious diseases such as colds and flu, bird flu, mild/common COVID-19 by the National Health Commission and the Administration of Traditional Chinese Medicine for more than 20 times. It is recommended by the program/guideline and has become the representative drug of traditional Chinese medicine in response to respiratory viral public health emergencies.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy